Clinical Trial Results:
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)
|
Summary
|
|
EudraCT number |
2016-003100-30 |
Trial protocol |
ES DE GB NO GR PT NL BE BG Outside EU/EEA FR PL AT IT |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Feb 2026
|
First version publication date |
27 Feb 2026
|
Other versions |
|
Summary report(s) |
EFC13429 EU RESULTS SUMMARY |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.